the only reason i bring up Phylogica potentially using CD40L as "blanket" of sorts in regards to collaborations it has formed with other Biotech companies is really just based on putting together a few pieces that the company has previously stated where CD40L is an area the company can speak publicly about as it is an internal project as opposed to any work with big pharma partnerships being commercially sensetive to them so requiring discretion.
Obviously BT collaborations hold benefits on both sides internal & partnership areas i just think there is much more at play than what appears as the recurring CD40 target statement.
PYC Price at posting:
6.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)